preprint · bioRxiv (Cold Spring Harbor Laboratory)
Abstract Introduction Zinc oxide nanoparticles (ZnONPs) have been synthesized using a wide range of techniques, including green chemistry, because of their versatility, cost effectiveness, and environmentally friendly nature, offering thereby interesting and inexpensive therapeutic options. This study aimed to develop zinc oxide nanoparticles as an anti-inflammatory agent using Aframomum citratum seed extract. Methodology ZnONPs were prepared by the reaction between zinc nitrate and an alkalineaqueous extract of A. citratum seeds. The isolated nanoparticles were then characterized using UV-Vis, FTIR, SEM/EDX, PXRD and TEM techniques. The toxicological profile was assessed at a limited dose of 2000 mg/kg in rats, and methods for heat denaturation of egg albumin, stabilization of red blood cell membranes and inhibition of carrageenan-induced plantar oedema were studied to assess anti-inflammatory properties. Results The formation of ZnONPs was observed by a color change and the appearance of the plasmon resonance peak at 360 nm in the UV-Vis spectrum while FTIR confirmed the presence of secondary metabolites; SEM confirmed the presence of multiform aggregates, and TEM visualize point like particles. EDS confirmed the presence of Zn atoms within the synthetized material. The toxicological profile studied showed no harmful signs; zinc oxide nanoparticles synthesized from A. citratum seed extract showed high inhibition percentages of 86 (1mg/mL); 77 (0.6mg/mL) and 79(1mg/mL) when subjected to inhibition of heat-induced egg albumin denaturation, red cell membrane stabilization and oedema induction by carrageenan respectively, not significatively different compared with diclofenac sodium as positive controls. Conclusion Zinc oxide nanoparticles synthesized and characterized from A. citratum seed extract act as a potent anti-inflammatory agent and are devoid of acute oral toxicity.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1101/2024.12.15.628600
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
